spacer
home > ict > Summer 2009
PUBLICATIONS

International Clinical Trials

ict
Summer 2009
At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. ICT provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of pharmaceuticals, take a look below at the range of articles featured in this issue of ICT.
   
Text
PDF
bullet
eCLINICAL
Observational studies may be common in epidemiological investigations, but Dominic Farmer of Cisiv illustrates how these studies, combined with web-enabled technologies, are ideally positioned to act as the bridge between pharma companies, patients, physicians and regulators.  
view
download pdf
John Blakeley of ERT tackles the issue of suicidality in clinical trials, and explains how electronic patient reported outcome tools are being used to increase the efficiency and accuracy of the monitoring process.  
view
download pdf
bullet
MEDICAL IMAGING AND QT STUDIES
As the value of operational and clinical metrics increases with time, global sponsors must work to engage CROs with the appropriate internal metrics and outsourcing approach to handle complex trials at the outset of the study; Richard Walovitch and Asli Memisoglu of WorldCare Clinical discuss.  
view
download pdf
While the pharmaceutical industry has rightly placed an emphasis on the significance of TQT studies, the fixation on demonstrating a negative signal has clouded the fact that these studies are only one part of the development programme of an NCE. Jörg Täubel and Keith Berelowitz at Richmond Pharmacology remind us of the three core elements of a successful TQT study.  
view
download pdf
bullet
Trial Management & Outsourcing
As recently as two decades ago, clinical trials were conducted almost exclusively in developed countries. Today, however, Latin America is widely recognised for its large number of treatment-naive subjects, qualified investigators, established regulatory systems and reasonable costs, as Victor Molina-Viamonte of Omnicare Clinical Research reports.  
view
download pdf
Getting to grips with translation can not only improve the quality of clinical research, but should also reduce the time to market for drugs by ensuring compliance with regulatory requirements; Steve Wilde of The Translation People explains more.  
view
download pdf
With clinical trials in China estimated, on average, to cost just 20 per cent of those in the West, many view the the country as the most attractive low-cost clinical trial location outside the US. Susan Wang of MDS Pharma Services investigates the current status of early stage capabilities in China.  
view
download pdf
In the current marketplace, global pharmaceutical and medical technology companies face many financial and organisational challenges; Brenda Hoeper and Cathy Thompson at i3 highlight the advantages of establishing a strategic alliance, and provide the building blocks for a successful, highly productive relationship.  
view
download pdf
As the recession bites, the focus of many organisations turns to cost savings, with outsourcing widely seen as a potential panacea. However, failing to invest in management structures, relationship-building and innovation can mean that outsourcing arrangements do not deliver the desired savings and profits, warn Jonathan Cooper-Bagnall and Kevin Deane of PA Consulting Group.  
view
download pdf
bullet
Ethics & Risk Management
With the pressure to produce results mounting on those organisations sponsoring and conducting clinical research projects, Frank Wells at the EFGCP asserts the need for an endorsed mechanism to investigate allegations of research misconduct, and to decide how national advisory bodies can best contribute to that mechanism.  
view
download pdf
Kathy Burns of Aon discusses the role that technology, and a risk management information system in particular, can play in streamlining the launch and management of clinical trials, as well as creating a holistic approach to managing risk.  
view
download pdf
bullet
Drug delivery & Therapeutics
Sandra Hageman and Edwin Janssen at Eurofind Medinet outline how detecting and characterising wanted and unwanted immune responses to new biopharmaceuticals is an essential task in order to ensure clinical trial safety and efficacy.  
view
download pdf
It is now possible to combine a single clinical study so that PET imaging can be obtained along with pharmacokinetic data, thus maximising the data output from a single trial, which in turn allows for a cost-effectived design explain Graham Lappin and Marie Simpson at Xceleron, and Oliver Langer, Department of Clinical Pharmacology, the Medical University of Vienna.  
view
download pdf
bullet
Labs & Logistics
Martin Crockard at Randox explains how finding the right quality control scheme is determined by the size, duration and complexity of each trial, and shows how a suitable control can be selected to fit every test.  
view
download pdf
The process of identifying a sourcing provider for a comparator is detailed and complex; Lekishia White of Multipharma, Inc explores the uniqueness of the comparator as a commodity, and the selection criteria for choosing the right provider.  
view
download pdf
The question of how best to deal with the pharmaceutical quality and CMP of the investigational product in an early stage of CMC development has received little coverage. Berend Oosterhuis and Arjen Akkerman of PRA International outline why the manufacture of a drug product for early exploratory studies should occur in a flexible, small-scale unit at the site of the clinical study.  
view
download pdf
   
spacer


Published quarterly in
February, May,
August, and November

News and Press Releases

SHIONOGI’S NOVEL ANTIBIOTIC, FETCROJA® (CEFIDEROCOL), HAS BEEN SELECTED BY UK’S NICE / NHSE&I AS PART OF AN ANTIMICROBIAL SUBSCRIPTION STYLE REIMBURSEMENT MODEL

The National Institute for Clinical and Health Excellence (NICE) and the National Health Service England and Improvement (NHSE&I) have recognised the potential of Shionogi’s innovative antibiotic, cefiderocol, and selected it for inclusion in this pilot reimbursement model which ‘de-links’ payment from volume of use Shionogi recognises the UK’s leadership role in introducing this first fully ‘delinked’ pilot reimbursement model, which is an important step in making the market for novel antibiotics more predictable and sustainable; we strongly believe in the introduction of further suitable pull incentives in order to help stimulate the antimicrobial development pipeline Fetcroja® (cefiderocol) is indicated for the treatment of infections due to aerobic Gram-negative bacteria in adults with limited treatment options1 Antimicrobial resistance (AMR) is a major health burden which results in over 700,000 deaths globally2 and 5,000 deaths per year in the UK3 from an infection with multidrug-resistant bacteria and this is predicted to kill 10 million people every year globally by 2050, unless action is taken2
More info >>

White Papers

Value-Added Processing and Quality By Design Principles Help Meet High-Quality Demands

West Pharmaceutical Services, Inc.

The current pharmaceutical market has faced a variety of challenges, including increasing expectations for quality from end-users and regulatory agencies driven by concern for patient safety. While pharmaceutical companies are working to assure that new quality and compliance paradigms are met, a balance must be achieved between the reality of managing costs in an effort to provide a product that meets the requirements of payers along with facilitating profitability in order to continue adequate business reinvestment.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement